Standardized Contrast-enhanced Ultrasound (CEUS) -Algorithms for the Non-invasive Diagnosis of Hepatocellular Carcinoma (HCC) in High-risk-patients - a Prospective German Multicenter Study
| Registry | NCT03405909, acronym ESCULAP |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 517 (Actual) |
| Sponsor | University Hospital Erlangen (Other) |
| Conditions | Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic, Liver Cirrhosis, Liver Cancer, Liver Neoplasms, Liver Diseases |
| Interventions | contrast enhanced ultrasound (CEUS), MRI, Histology (Diagnostic test) |
| Dates | start 2018-04-21, primary completion 2019-04-06, completion 2019-04-06, first posted 2018-01-23, last updated 2021-03-02 |
| Locations | 1 site in Germany |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Hepatocellular Carcinoma All trials for Cholangiocarcinoma, Intrahepatic All trials of contrast enhanced ultrasound (CEUS) All trials of MRI
Aim of this prospective national multicenter study is to improve standardization of contrast-enhanced ultrasound (CEUS) in the non-invasive diagnosis of hepatocellular carcinoma (HCC) in high-risk patients.
The study is funded by the German Society for Ultrasound in Medicine (DEGUM).
To date, CEUS criteria for non-invasive diagnosis of HCC include arterial phase hyperenhancement, followed by contrast washout in the portal venous or late phase. We would like to investigate the following points:
1. whether arterial hyperenhancement alone is sufficient for the definite diagnosis of HCC in cirrhosis with CEUS
2. whether a further clearly-defined point of assessment in the late phase after 4-6 minutes is of additional diagnostic value in focal liver lesions showing no contrast washout after 3 minutes
3. diagnostic value of CEUS-based standardised diagnostic algorithms (ESCULAP = Erlanger Synopsis of Contrast Enhanced Ultrasound for Liver lesion Assessment in Patients at risk; CEUS LI-RADS = Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System) for non-invasive diagnosis of HCC in high-risk patients (diagnostic accuracy, interobserver-variability, feasability in clinical Routine).
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Patients at risk for HCC | Diagnostic Test: contrast enhanced ultrasound (CEUS); Diagnostic Test: MRI; Diagnostic Test: Histology | Patients with any of the following conditions: liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * high risk for HCC * focal liver lesion on B-mode ultrasound Exclusion Criteria: * pre-treated HCC lesion * systemic therapy for HCC (sorafenib, regorafenib and others)
| Facility | City | Country | Status |
|---|---|---|---|
| University Hospital Erlangen, Department of Medicine 1 | Erlangen, Bavaria | Germany |